FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3148342899> ?p ?o ?g. }

• W3148342899 endingPage "3609" @default.
• W3148342899 startingPage "3602" @default.
• W3148342899 abstract "Abstract Purpose: MEDI3726 is an antibody–drug conjugate targeting the prostate-specific membrane antigen and carrying a pyrrolobenzodiazepine warhead. This phase I study evaluated MEDI3726 monotherapy in patients with metastatic castration-resistant prostate cancer after disease progression on abiraterone and/or enzalutamide and taxane-based chemotherapy. Patients and Methods: MEDI3726 was administered at 0.015–0.3 mg/kg intravenously every 3 weeks until disease progression/unacceptable toxicity. The primary objective was to assess safety, dose-limiting toxicities (DLT), and MTD/maximum administered dose (MAD). Secondary objectives included assessment of antitumor activity, pharmacokinetics, and immunogenicity. The main efficacy endpoint was composite response, defined as confirmed response by RECIST v1.1, and/or PSA decrease of ≥50% after ≥12 weeks, and/or decrease from ≥5 to &lt;5 circulating tumor cells/7.5 mL blood. Results: Between February 1, 2017 and November 13, 2019, 33 patients received MEDI3726. By the data cutoff (January 17, 2020), treatment-related adverse events (TRAE) occurred in 30 patients (90.9%), primarily skin toxicities and effusions. Grade 3/4 TRAEs occurred in 15 patients (45.5%). Eleven patients (33.3%) discontinued because of TRAEs. There were no treatment-related deaths. One patient receiving 0.3 mg/kg had a DLT of grade 3 thrombocytopenia. The MTD was not identified; the MAD was 0.3 mg/kg. The composite response rate was 4/33 (12.1%). MEDI3726 had nonlinear pharmacokinetics with a short half-life (0.3–1.8 days). The prevalence of antidrug antibodies was 3/32 (9.4%), and the incidence was 13/32 (40.6%). Conclusions: Following dose escalation, no MTD was identified. Clinical responses occurred at higher doses, but were not durable as patients had to discontinue treatment due to TRAEs." @default.
• W3148342899 created "2021-04-13" @default.
• W3148342899 creator A5001258614 @default.
• W3148342899 creator A5003842671 @default.
• W3148342899 creator A5012867126 @default.
• W3148342899 creator A5030087036 @default.
• W3148342899 creator A5040578796 @default.
• W3148342899 creator A5041286537 @default.
• W3148342899 creator A5047053999 @default.
• W3148342899 creator A5050042851 @default.
• W3148342899 creator A5050931392 @default.
• W3148342899 creator A5058484248 @default.
• W3148342899 creator A5072378199 @default.
• W3148342899 creator A5081246052 @default.
• W3148342899 creator A5083177385 @default.
• W3148342899 creator A5083508937 @default.
• W3148342899 creator A5084109278 @default.
• W3148342899 creator A5088882130 @default.
• W3148342899 date "2021-04-01" @default.
• W3148342899 modified "2023-10-18" @default.
• W3148342899 title "Phase I Study of MEDI3726: A Prostate-Specific Membrane Antigen-Targeted Antibody–Drug Conjugate, in Patients with mCRPC after Failure of Abiraterone or Enzalutamide" @default.
• W3148342899 cites W2053554578 @default.
• W3148342899 cites W2113073012 @default.
• W3148342899 cites W2127373755 @default.
• W3148342899 cites W2278392405 @default.
• W3148342899 cites W2511115146 @default.
• W3148342899 cites W2531217210 @default.
• W3148342899 cites W2549780925 @default.
• W3148342899 cites W2763982071 @default.
• W3148342899 cites W2767025650 @default.
• W3148342899 cites W2887583157 @default.
• W3148342899 cites W2896496903 @default.
• W3148342899 cites W2903196646 @default.
• W3148342899 cites W2908948837 @default.
• W3148342899 cites W2909920862 @default.
• W3148342899 cites W2963473092 @default.
• W3148342899 cites W2973098277 @default.
• W3148342899 cites W3032629571 @default.
• W3148342899 doi "https://doi.org/10.1158/1078-0432.ccr-20-4528" @default.
• W3148342899 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33795255" @default.
• W3148342899 hasPublicationYear "2021" @default.
• W3148342899 type Work @default.
• W3148342899 sameAs 3148342899 @default.
• W3148342899 citedByCount "16" @default.
• W3148342899 countsByYear W31483428992021 @default.
• W3148342899 countsByYear W31483428992022 @default.
• W3148342899 countsByYear W31483428992023 @default.
• W3148342899 crossrefType "journal-article" @default.
• W3148342899 hasAuthorship W3148342899A5001258614 @default.
• W3148342899 hasAuthorship W3148342899A5003842671 @default.
• W3148342899 hasAuthorship W3148342899A5012867126 @default.
• W3148342899 hasAuthorship W3148342899A5030087036 @default.
• W3148342899 hasAuthorship W3148342899A5040578796 @default.
• W3148342899 hasAuthorship W3148342899A5041286537 @default.
• W3148342899 hasAuthorship W3148342899A5047053999 @default.
• W3148342899 hasAuthorship W3148342899A5050042851 @default.
• W3148342899 hasAuthorship W3148342899A5050931392 @default.
• W3148342899 hasAuthorship W3148342899A5058484248 @default.
• W3148342899 hasAuthorship W3148342899A5072378199 @default.
• W3148342899 hasAuthorship W3148342899A5081246052 @default.
• W3148342899 hasAuthorship W3148342899A5083177385 @default.
• W3148342899 hasAuthorship W3148342899A5083508937 @default.
• W3148342899 hasAuthorship W3148342899A5084109278 @default.
• W3148342899 hasAuthorship W3148342899A5088882130 @default.
• W3148342899 hasBestOaLocation W31483428991 @default.
• W3148342899 hasConcept C111113717 @default.
• W3148342899 hasConcept C112705442 @default.
• W3148342899 hasConcept C121608353 @default.
• W3148342899 hasConcept C126322002 @default.
• W3148342899 hasConcept C126894567 @default.
• W3148342899 hasConcept C143998085 @default.
• W3148342899 hasConcept C197934379 @default.
• W3148342899 hasConcept C203092338 @default.
• W3148342899 hasConcept C2776551883 @default.
• W3148342899 hasConcept C2780192828 @default.
• W3148342899 hasConcept C2781406297 @default.
• W3148342899 hasConcept C535046627 @default.
• W3148342899 hasConcept C61367390 @default.
• W3148342899 hasConcept C71924100 @default.
• W3148342899 hasConcept C90924648 @default.
• W3148342899 hasConcept C98274493 @default.
• W3148342899 hasConceptScore W3148342899C111113717 @default.
• W3148342899 hasConceptScore W3148342899C112705442 @default.
• W3148342899 hasConceptScore W3148342899C121608353 @default.
• W3148342899 hasConceptScore W3148342899C126322002 @default.
• W3148342899 hasConceptScore W3148342899C126894567 @default.
• W3148342899 hasConceptScore W3148342899C143998085 @default.
• W3148342899 hasConceptScore W3148342899C197934379 @default.
• W3148342899 hasConceptScore W3148342899C203092338 @default.
• W3148342899 hasConceptScore W3148342899C2776551883 @default.
• W3148342899 hasConceptScore W3148342899C2780192828 @default.
• W3148342899 hasConceptScore W3148342899C2781406297 @default.
• W3148342899 hasConceptScore W3148342899C535046627 @default.
• W3148342899 hasConceptScore W3148342899C61367390 @default.
• W3148342899 hasConceptScore W3148342899C71924100 @default.
• W3148342899 hasConceptScore W3148342899C90924648 @default.
• W3148342899 hasConceptScore W3148342899C98274493 @default.
• W3148342899 hasFunder F4320307770 @default.

• next